Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy

NCT04215861 | Unknown

• 1 other identifier: PJ-KS-KY-2019-135
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.

Conditions

Lung Cancer; Liver Cancer; Stomach Cancer; Breast Cancer

Outcome Measures

Primary Outcomes (2)

• Raman spectra

  Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected to analyze the signal changes of Raman spectrum

  the 1st day before operation

• Raman spectra

  Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected to analyze the signal changes of Raman spectrum

  the 1st day after operation

Secondary Outcomes (3)

• progression-free survival

  through study completion, an average of 1 year

• overall survival

  through study completion, an average of 1 year

• objective response rate

  through study completion, an average of 1 year

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* 18-80 years old; * The patient whose tumor (tissue or cell) was first diagnosed by pathology; * Plan to receive routine clinical treatment: chemotherapy, radiotherapy, surgery, intervention, targeted therapy, traditional Chinese medicine treatment and biological immunotherapy; * Have relevant indications for treatment and have no contraindications;

You may qualify if:

• years old;
• The patient whose tumor (tissue or cell) was first diagnosed by pathology;
• Plan to receive routine clinical treatment: chemotherapy, radiotherapy, surgery, intervention, targeted therapy, traditional Chinese medicine treatment and biological immunotherapy;
• Have relevant indications for treatment and have no contraindications;

You may not qualify if:

• Severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases, etc.);
• Other circumstances considered inappropriate by the researcher to participate in the study;

Sponsors & Collaborators

• The First Affiliated Hospital of Dalian Medical University: lead

Study Sites (1)

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, 116000, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Liver Neoplasms; Stomach Neoplasms; Breast Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Digestive System Neoplasms; Digestive System Diseases; Liver Diseases; Gastrointestinal Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Xiaonan Cui, MD,PhD

  The First Affiliated Hospital of Dalian Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiaonan Cui, MD,PhD

CONTACT

+8618098876725; cxn23@sina.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2019
• First Posted: January 2, 2020
• Study Start: October 1, 2019
• Primary Completion: October 1, 2021
• Study Completion: October 1, 2021
• Last Updated: January 2, 2020

Record last verified: 2019-12

Locations

CN (1)